Narsis Daftarian

Narsis Daftarian

Auto-generated profile, based on publicly available information

Narsis Daftarian

University of British Columbia Vancouver British Columbia Canada

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2007 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
MEMorteza Entezari
Morteza Entezari
ZRZhaleh Rajavi
Zhaleh Rajavi
NSNeda Sedighi
Neda Sedighi
NDNarssis Daftarian
Narssis Daftarian
MSMasoumeh Sanagoo
Masoumeh Sanagoo

1 January 2017 in Journal of Ophthalmic and Vision Research
Verified
Journal Article
Open access
PDF file
HAHamid Ahmadieh
Hamid Ahmadieh
HBHossein Baharvand
Hossein Baharvand
LSLeila Satarian
Leila Satarian
RNRamin Nourinia
Ramin Nourinia
SSSare Safi
Sare Safi
NANasser Aghdami
Nasser Aghdami
Purpose: To examine the safety of a single intravitreal injection of autologous bone Marrow Mesenchymal stem cells (MSCs) in patients with advanced retinitis pigmentosa (RP). Methods: A prospective, phase I, nonrandomized, open-label study was conducted on 3 eyes of 3 volunteers with advanced RP. Visual acuity, slit-lamp examination, fundus examination, optical coherence tomography, fundus auto-fluorescence, fluorescein angiography and multifocal electroretinography were performed before and after an intravitreal injection of approximately one-million MSCs. The patients were followed for one year. Further evaluation of MSCs was performed by injection of these cells into the mouse vitreous cavity. Results: No, adverse events were observed in eyes of 2 out of 3 patients after transplantation of MSCs. These patients reported improvements in perception of the light after two weeks, which lasted for 3 months. However, severe fibrous tissue proliferation was observed in the vitreous cavity and retrolental space of the third patient's eye, which led to tractional retinal detachment (TRD), iris neovascularization and formation of mature cataract. Injection of this patient's MSCs into the vitreous cavity of mice also resulted in fibrosis; however, intravitreal injections of the two other patients' cells into the mouse vitreous did not generate any fibrous tissue. Conclusion: Intravitreal injection of autologous bone marrow MSCs into patients' eyes with advanced RP does not meet safety standards. Major side effects of this therapy can include fibrosis and TRD. We propose thorough evaluation of MSCs prior to transplantation by intravitreal injection in the laboratory animals.\

3 August 2012 in Stem Cells and Development
Verified
Journal Article
Closed access
AZAzadeh Zahabi
Azadeh Zahabi
ESEbrahim Shahbazi
Ebrahim Shahbazi
HAHamid Ahmadieh
Hamid Ahmadieh
SHSeyedeh-Nafiseh Hassani
Seyedeh-Nafiseh Hassani
MTMehdi Totonchi
Mehdi Totonchi
HBHossein Baharvand
Hossein Baharvand
We describe a new, efficient protocol that involves the serial addition of noggin, basic fibroblast growth factor (bFGF), retinoic acid, and sonic hedgehog (Shh) for the differentiation of human induced pluripotent stem cells (hiPSC) to retinal pigmented epithelium (RPE) in a serum- and feeder-free adherent condition. hiPSC-RPE cells exhibited RPE morphology and specific molecular markers. Additionally, several hiPSC lines were generated from retinal-specific patients with Leber's congenital amaurosis, Usher syndrome, two patients with retinitis pigmentosa, and a patient with Leber's hereditary optic neuropathy. The RPE cells generated from these disease-specific hiPSCs expressed specific markers by the same RPE lineage-directed differentiation protocol. These findings indicate a new short-term, simple, and efficient protocol for differentiation of hiPSCs to RPE cells. Such specific retinal disease-specific hiPSCs offer an unprecedented opportunity to recapitulate normal and pathologic formation of human retinal cells in vitro, thereby enabling pharmaceutical screening, and potentially autologous cell replacement therapies for retinal diseases.

1 June 2007 in Journal of Glaucoma
Verified
Journal Article
Closed access
ZBZohreh Behrouzi
Zohreh Behrouzi
HRHossein Mohammad Rabei
Hossein Mohammad Rabei
FAFereidoon Azizi
Fereidoon Azizi
NDNarsis Daftarian
Narsis Daftarian
YMYadollah Mehrabi
Yadollah Mehrabi
MMMehrdad Mohammadpour
Mehrdad Mohammadpour
To determine the prevalence of open-angle glaucoma (OAG), glaucoma suspects (GS), and ocular hypertension (OHT) in patients with thyroid-related immune orbitopathy (TRIO) and compare it with a control group. In this cross-sectional analytic study, 233 eyes of 117 patients with TRIO (case group) and 240 eyes of 120 normal age and sex-matched individuals (control group) underwent complete ocular examinations. Grave orbitopathy (GO) was diagnosed by clinical examinations with the help of an endocrinologist and para clinic tests. Controls were selected among apparently healthy individuals with no history of previous orbitopathy or thyroid diseases. Prevalence of OAG and OHT was 2.5% and 8.5% in the case group, respectively. In contrast, OAG was detected in only 2 eyes (0.8%) of the control group and there were no instances of GS or OHT in the control group. Although the prevalence of OAG and GS were higher in cases than controls, this difference was not statistically significant. However, OHT was more common in cases (P<0.01). Ten eyes in the case group (4.3%) developed compressive optic neuropathy (CON); high intraocular pressure was detected in 5 of them (2.1%). All cases of OAG and GS in the case group were classified as stage 3 or higher of No symptoms or signs, Only signs no symptoms, Soft tissue, Proptosis, Extraocular muscle, Cornea, Sight loss. Active GO was only more prevalent in patients with OHT (P<0.001). The prevalence of OHT was higher in cases with GO than age and sex-matched controls. Ophthalmologic examinations including intraocular pressure measurement (and if needed automated visual fields) should be regularly performed in patients with GO particularly in higher stages and those with active disease.

1 February 2016 in Neurobiology of Aging
Verified
Journal Article
Closed access
EJElham Jaberi
Elham Jaberi
MRMohammad Rohani
Mohammad Rohani
GSGholam Ali Shahidi
Gholam Ali Shahidi
SNShahriar Nafissi
Shahriar Nafissi
EAEhsan Arefian
Ehsan Arefian
EEElahe Elahi
Elahe Elahi

11 March 2016 in Scientific Reports
Verified
Journal Article
Open access
SSSheila Smiley
Sheila Smiley
PNPhilip E. Nickerson
Philip E. Nickerson
LCLacrimioara Comanita
Lacrimioara Comanita
NDNarsis Daftarian
Narsis Daftarian
AEAhmed El-Sehemy
Ahmed El-Sehemy
VWValerie A. Wallace
Valerie A. Wallace
We report successful retinal cone enrichment and transplantation using a novel cone-GFP reporter mouse line. Using the putative cone photoreceptor-enriched transcript Coiled-Coil Domain Containing 136 (Ccdc136) GFP-trapped allele, we monitored developmental reporter expression, facilitated the enrichment of cones, and evaluated transplanted GFP-labeled cones in wildtype and retinal degeneration mutant retinas. GFP reporter and endogenous Ccdc136 transcripts exhibit overlapping temporal and spatial expression patterns, both initiated in cone precursors of the embryonic retina and persisting to the adult stage in S and S/M opsin+ cones as well as rod bipolar cells. The trapped allele does not affect cone function or survival in the adult mutant retina. When comparing the integration of GFP+ embryonic cones and postnatal Nrl−/− ‘cods’ into retinas of adult wildtype and blind mice, both cell types integrated and exhibited a degree of morphological maturation that was dependent on donor age. These results demonstrate the amenability of the adult retina to cone transplantation using a novel transgenic resource that can advance therapeutic cone transplantation in models of age-related macular degeneration.